SAB4301397
Anti-phospho-BRCA2 (pSer3291) antibody produced in rabbit
affinity isolated antibody
别名:
BRCA1/BRCA2-containing complex, BRCA2, BRCC2, subunit 2
biological source
rabbit
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
>350 kDa
species reactivity
rat, human, mouse
concentration
1.0 mg/mL
technique(s)
western blot: 1:500-1:1000 (Cell Lysate)
isotype
IgG
accession no.
NP_000050.2.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... BRCA2(675)
Immunogen
Peptide sequence around phosphorylation site of Serine 3291 (F-V-S(p)-P-A) derived from Human BRCA2.
Biochem/physiol Actions
The antibody detects endogenous levels of BRCA2 only when phosphorylated at serine 3291.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
Gro Elise Rødland et al.
Frontiers in oncology, 9, 1301-1301 (2019-12-19)
The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL). Herein we have
Sissel Hauge et al.
Oncotarget, 8(7), 10966-10979 (2016-12-29)
Recent studies have shown synergistic cytotoxic effects of simultaneous Chk1- and Wee1-inhibition. However, the mechanisms behind this synergy are not known. Here, we present a flow cytometry-based screen for compounds that cause increased DNA damage in S-phase when combined with
Sissel Hauge et al.
Cell cycle (Georgetown, Tex.), 18(8), 834-847 (2019-04-05)
The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持